Episurf Medical AB (STU:16E) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Episurf Medical AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Episurf Medical AB Valuation Rank Related Terms

Episurf Medical AB Business Description

Other Exchanges EPIS B:Sweden0QUT:UK
Address Karlavagen 60, Stockholm, SWE, 114 49
Episurf Medical AB is a medical device company. The company develops, manufactures, and commercializes solutions for the repair of the local cartilage damage in human joints. Its first patient-specific product portfolio, the knee portfolio, consists of the existing products Episealer Condyle Solo and Episealer Trochlea Solo, Episealer Femoral Twin, Epiguide MOS, and Epioscopy. Episealer Patellofemoral System for the treatment of osteoarthritis limited to thepatellofemoral part of the knee joint. The company is forming a new strategic business segment through the acquisition of real estate assets.